{
    "nctId": "NCT00614978",
    "briefTitle": "Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer",
    "officialTitle": "Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Brain Metastases, HER2 Positive",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomide",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 - 70 years\n* Women with cytologically or histologically proven metastatic breast cancer with recurrent / progressive brain metastases evaluable by MRI, after standard treatment with surgery (at least 3 weeks prior) or WBRT (at least 3 weeks prior) or stereotactic RT (at least 1 week prior); or otherwise deemed as unsuitable for standard treatment in the first instance\n* Known HER-2 positive status (immunohistochemistry (IHC) 3+ Fluorescence In Situ Hybridization (FISH) positive )\n* Previous chemotherapy (adjuvant and metastatic regimens) allowed\n* Previous treatment with trastuzumab allowed (Trastuzumab to be discontinued prior to study entry)\n* At least one measurable lesion in the brain, defined as any lesion \\>5mm in longest dimension on T1-weighted, gadolinium-enhanced MRI\n* Expected life-expectancy of more than 3 months\n* ECOG performance status of 0, 1 or 2\n* Adequate bone marrow, renal and hepatic functionsLVEF\n* LVEF \\>50% measured by echocardiography or MUGA scan\n* Concomitant corticosteroids and anti-convulsants for symptomatic brain metastases are allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}